Knight Therapeutics Inc. (GUD.TO)
CAD 5.77
(3.22%)
CAD 5.77
(3.22%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 945.49 Million CAD | -10.37% |
| 2022 | 1.05 Billion CAD | 6.35% |
| 2021 | 991.89 Million CAD | -4.6% |
| 2020 | 1.03 Billion CAD | -20.35% |
| 2019 | 1.3 Billion CAD | 24.1% |
| 2018 | 1.05 Billion CAD | 4.56% |
| 2017 | 1 Billion CAD | 1.54% |
| 2016 | 990.77 Million CAD | 52.66% |
| 2015 | 648.98 Million CAD | 33.37% |
| 2014 | 486.61 Million CAD | 48661317000.0% |
| 2013 | 1.00 CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 968.2 Million CAD | 2.4% |
| 2024 Q2 | 945.36 Million CAD | -2.36% |
| 2023 Q4 | 945.49 Million CAD | -6.49% |
| 2023 Q2 | 1.01 Billion CAD | -2.97% |
| 2023 Q1 | 1.04 Billion CAD | -0.95% |
| 2023 Q3 | 1.01 Billion CAD | -0.26% |
| 2023 FY | 945.49 Million CAD | -10.37% |
| 2022 Q3 | 1.03 Billion CAD | 3.42% |
| 2022 Q2 | 1 Billion CAD | 0.57% |
| 2022 FY | 1.05 Billion CAD | 6.35% |
| 2022 Q1 | 995.42 Million CAD | 0.36% |
| 2022 Q4 | 1.05 Billion CAD | 1.88% |
| 2021 Q1 | 1 Billion CAD | -3.74% |
| 2021 Q4 | 991.89 Million CAD | -4.41% |
| 2021 Q3 | 1.03 Billion CAD | -0.58% |
| 2021 Q2 | 1.04 Billion CAD | 4.28% |
| 2021 FY | 991.89 Million CAD | -4.6% |
| 2020 Q3 | 1.01 Billion CAD | -17.21% |
| 2020 Q4 | 1.03 Billion CAD | 2.54% |
| 2020 FY | 1.03 Billion CAD | -20.35% |
| 2020 Q2 | 1.22 Billion CAD | -3.35% |
| 2020 Q1 | 1.26 Billion CAD | -2.92% |
| 2019 FY | 1.3 Billion CAD | 24.1% |
| 2019 Q4 | 1.3 Billion CAD | 27.69% |
| 2019 Q3 | 1.02 Billion CAD | -4.85% |
| 2019 Q2 | 1.07 Billion CAD | 1.53% |
| 2019 Q1 | 1.05 Billion CAD | 0.6% |
| 2018 Q4 | 1.05 Billion CAD | 1.0% |
| 2018 Q2 | 1.02 Billion CAD | 1.21% |
| 2018 Q1 | 1.01 Billion CAD | 1.08% |
| 2018 FY | 1.05 Billion CAD | 4.56% |
| 2018 Q3 | 1.04 Billion CAD | 1.19% |
| 2017 Q2 | 991.98 Million CAD | -0.23% |
| 2017 Q4 | 1 Billion CAD | 1.26% |
| 2017 FY | 1 Billion CAD | 1.54% |
| 2017 Q1 | 994.29 Million CAD | 0.36% |
| 2017 Q3 | 993.46 Million CAD | 0.15% |
| 2016 Q2 | 867.99 Million CAD | 35.98% |
| 2016 Q3 | 877.9 Million CAD | 1.14% |
| 2016 Q4 | 990.77 Million CAD | 12.86% |
| 2016 FY | 990.77 Million CAD | 52.66% |
| 2016 Q1 | 638.33 Million CAD | -1.64% |
| 2015 Q3 | 627.82 Million CAD | 18.43% |
| 2015 FY | 648.98 Million CAD | 33.37% |
| 2015 Q4 | 648.98 Million CAD | 3.37% |
| 2015 Q2 | 530.13 Million CAD | 0.9% |
| 2015 Q1 | 525.42 Million CAD | 7.98% |
| 2014 Q4 | 486.61 Million CAD | 86.0% |
| 2014 Q2 | 260.32 Million CAD | 201.01% |
| 2014 Q3 | 261.61 Million CAD | 0.5% |
| 2014 Q1 | 86.48 Million CAD | 0.0% |
| 2014 FY | 486.61 Million CAD | 48661317000.0% |
| 2013 Q3 | 867.41 Thousand CAD | 0.0% |
| 2013 FY | 1.00 CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aurora Cannabis Inc. | 838.67 Million CAD | -12.737% |
| Avicanna Inc. | 21.97 Million CAD | -4203.347% |
| Avant Brands Inc. | 82.55 Million CAD | -1045.33% |
| Cardiol Therapeutics Inc. | 36.7 Million CAD | -2476.24% |
| Crescita Therapeutics Inc. | 24.59 Million CAD | -3743.78% |
| MediPharm Labs Corp. | 63.93 Million CAD | -1378.788% |
| OrganiGram Holdings Inc. | 298.45 Million CAD | -216.796% |
| Canopy Growth Corporation | 1.3 Billion CAD | 27.288% |
| Willow Biosciences Inc. | 6.67 Million CAD | -14068.935% |
| Auxly Cannabis Group Inc. | 261.9 Million CAD | -261.007% |